StockNews.com Lowers Alimera Sciences (NASDAQ:ALIM) to Hold

StockNews.com lowered shares of Alimera Sciences (NASDAQ:ALIM) from a buy rating to a hold rating in a research note released on Friday.

Separately, Maxim Group initiated coverage on shares of Alimera Sciences in a research note on Monday, March 25th. They issued a buy rating and a $10.00 price objective for the company.

Alimera Sciences Trading Up 0.6 %

Shares of NASDAQ:ALIM opened at $3.54 on Friday. Alimera Sciences has a 1 year low of $1.56 and a 1 year high of $4.38. The firm has a fifty day moving average price of $3.75 and a 200 day moving average price of $3.61. The company has a current ratio of 2.39, a quick ratio of 2.31 and a debt-to-equity ratio of 1.40. The stock has a market capitalization of $185.32 million, a PE ratio of -1.64 and a beta of 1.18.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.09). Alimera Sciences had a negative net margin of 24.93% and a negative return on equity of 130.90%. The company had revenue of $26.31 million for the quarter, compared to analyst estimates of $25.10 million. During the same period in the prior year, the company posted ($0.54) EPS. Analysts expect that Alimera Sciences will post 0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Alimera Sciences

Several large investors have recently bought and sold shares of ALIM. AIGH Capital Management LLC acquired a new position in shares of Alimera Sciences during the third quarter valued at about $7,355,000. Stonepine Capital Management LLC bought a new position in Alimera Sciences during the third quarter valued at about $12,349,000. Worth Venture Partners LLC acquired a new position in shares of Alimera Sciences in the third quarter valued at $1,840,000. Northern Trust Corp acquired a new stake in Alimera Sciences during the fourth quarter worth $61,000. Finally, Vanguard Group Inc. increased its holdings in Alimera Sciences by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 146,686 shares of the biopharmaceutical company’s stock valued at $455,000 after buying an additional 5,293 shares during the period. 99.83% of the stock is currently owned by institutional investors and hedge funds.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).